Transdermal Eperisone Elicits more Potent and Longer-Lasting Muscle Relaxation than Oral Eperisone

Abstract

Eperisone hydrochloride is widely used for the treatment of plasticity to relieve muscle stiffness and back pain. However, oral eperisone has a very low bioavailability and short muscle relaxant activity, because of the profound intestinal first-pass metabolism. To improve the efficacy and compliance of eperisone, we designed a new dosage form, a transdermal patch, and evaluated the efficacy of the eperisone patch with the muscle relaxant activity of rats. The muscle relaxant activity was assessed by the measurement of forelimb grip strength and hanging test in rats. The transdermal patch of eperisone showed significantly enhanced muscle relaxant activity at 0.5 1.5 and 3 cm²/200 g rat (1.39, 4.17 and 8.33 mg of eperisone hydrochloride/kg, respectively) in a dose-dependent manner and the effects lasted over 24 h. Even though oral eperisone hydrochloride showed significant muscle relaxant activity at 12.5, 25 and 50 mg/kg in a dose-dependent manner, the activity lasted only 1 or 2 h after administration. These results suggest that eperisone as transdermal patch form showed efficient absorption with more potent and longer-lasting muscle relaxant activity than oral solution. The transdermal patch form of eperisone will increase the efficacy and compliance in the clinical use of eperisone.

Dermal and Transdermal Drug Delivery Systems: Current and Future Prospects

“…• Sustained and controlled delivery over a prolonged period of time (Varvel et al 1989;Yang et al 2004). …”

Aging and exercise affect the level of protein acetylation and SIRT1 activity in cerebellum of male rats

“…The forelimb strength of the animals was assessed by using a gripping test on the pole as described by Yang et al (2004).…”

Minor and Short-Acting Analgesics, Including Opioid Combination Products

“…The bioavailability of ER tramadol is comparable to that of IR tramadol and demonstrates steady-state bioequivalence (100,200, 300 mg) was found to be superior to placebo in average change from baseline pain from 1 through 12 weeks in a randomized trial of OA of the knee. The bioavailability of ER tramadol is comparable to that of IR tramadol and demonstrates steady-state bioequivalence (100,200, 300 mg) was found to be superior to placebo in average change from baseline pain from 1 through 12 weeks in a randomized trial of OA of the knee.…”